Etodolac

A nonsteroidal anti-inflammatory drug that acts as a non-selective inhibitor of COX with IC50 of 53.5 nM; also inhibits PGHS-2 and shows 10-fold selectivity over PGHS-1; exhibits 10-fold selectivity for inhibition of PGHS-2 mediated TxB2 production in a human whole blood assay; Etodolac is licensed for the treatment of inflammation and pain caused by osteoarthritis and rheumatoid arthritis.Pain Approved (In Vitro) :Post-marketing studies demonstrated that etodolac inhibition of cyclooxygenase is somewhat COX-2 selective similar to celecoxib and other "COX-2 inhibitors." Unlike rofecoxib, both etodolac and celecoxib can fully inhibit COX-1 and are designated as having "preferential selectivity" toward COX-2. The (inactive against COX) r-enantiomer of etodolac inhibits beta-catenin levels in hepatoma cells.